What is retatrutide, and is it available?
Let us start with the most important point, because it shapes everything else. Retatrutide is an experimental drug. It is still being studied in clinical trials — the careful research studies that test whether a new medicine works and is safe. It is not approved by the FDA (the part of the US government that decides which medicines are safe to sell). And it is not something you can buy or pick up at a pharmacy.
So why is everyone talking about it? Because of how it is built. You may have heard of weight-loss shots like Ozempic and Mounjaro. Those copy natural gut messages — chemical signals your gut sends after you eat that tell your brain you are full. Ozempic copies one of those signals. Mounjaro copies two. Retatrutide is designed to copy three at once.
The three signals it copies are called GIP, GLP-1, and glucagon. You do not need to memorize those names. The simple idea is this: it is like turning on three light switches in the same room instead of one or two. Scientists hoped that hitting three targets at once might do more, and early studies suggest it can. But "early studies suggest" is very different from "proven and approved" — and that gap is the whole story here.
It is worth slowing down on what "in clinical trials" really means, because it is easy to gloss over. A clinical trial is a tightly controlled study. People volunteer, they are watched closely by doctors, and the results are written up and checked by other scientists. Being in trials is the normal, responsible path every new medicine has to walk before anyone can buy it. It is also a sign that the final answers are not in yet. A drug can look wonderful in early trials and still hit a snag later. That is exactly why the testing keeps going.
How does retatrutide work, and why might three signals help?
To understand the benefits, it helps to know what those three copied signals actually do. The names again are GIP, GLP-1, and glucagon. Each is a natural hormone your body already makes, and each nudges your metabolism in a slightly different way. Retatrutide is a single molecule built to switch on all three of their receptors at once — the docking points those hormones normally use.
Two of the signals, GIP and GLP-1, mostly work by turning down appetite. They are part of the natural "I am full" message your gut sends after a meal, and copying them helps people eat less without constantly fighting hunger. The approved weight shots most people have heard of lean on one or both of these.
The third signal, glucagon, is the twist. In the laboratory work that first described retatrutide, researchers reported that adding glucagon activity increased energy expenditure — the amount of energy the body burns — on top of the appetite-lowering effect of the other two. In plainer words: two of the switches help you take in less, and the third may help you burn a little more. That combination is the reason scientists were curious whether three signals could outdo one or two.
It is important not to oversell this. The three-signal design is the rationale, and the early human studies are encouraging, but "promising design" is not the same as "proven in large trials." The mechanism explains why retatrutide was worth testing — not that it is a finished, approved treatment.
What benefits did the studies show?
The headline finding is weight loss. In an early study of adults with obesity, people who took the highest dose for about a year lost, on average, around a quarter of their body weight — about 24%. To put that in everyday terms, that is roughly 58 pounds for someone who started at 240 pounds. That is one of the largest weight-loss numbers ever reported for any single weight medicine.
The study also looked at how many people hit certain milestones at that highest dose, and the numbers were striking. Everyone in that group — 100% — lost at least 5% of their body weight. About 93% lost at least 10%, and around 83% lost 15% or more. Hitting those marks across nearly an entire treatment group is unusual for any weight medicine, let alone in an early study.
It helps to see those numbers next to the approved medicines people already know. In their own large studies, tirzepatide (the drug in Mounjaro and Zepbound) led to about 21% weight loss, and semaglutide (the drug in Ozempic and Wegovy) led to about 15%. Retatrutide's early number looks higher. But there is a catch worth repeating: those two are FDA-approved and available, and retatrutide is not. You cannot compare them as if they were equal choices, because only two of them are actually choices.
One more thing to keep in mind. This was an early-stage study, which scientists call a phase 2 trial. Early studies often use carefully chosen groups of people and shorter time frames. The very large, longer studies that come next — called phase 3 — frequently land on somewhat smaller numbers. So treat that 24% as an encouraging early signal, not a promise of what any one person would get.
Why do the numbers tend to shrink in bigger studies? A few plain reasons. Larger studies include a much wider mix of people, closer to the real world. They run longer, so there is more time for everyday life to get in the way. And early studies sometimes happen to enroll people who respond especially well. None of that is a trick or a failure — it is just how science homes in on the honest, average answer. The point is simply that the first big number you hear is rarely the final one.
| Weight-loss milestone | Participants reaching it (12 mg, 48 wk) |
|---|---|
| Lost ≥5% of body weight | 100% |
| Lost ≥10% of body weight | 93% |
| Lost ≥15% of body weight | 83% |
What about liver fat?
The other finding that got scientists' attention was the liver. Some people carry extra fat inside the liver itself. Doctors call this fatty liver disease. Over time, too much fat in the liver can cause inflammation and damage, so getting that fat down is genuinely good for health.
In a part of the research that focused on people with fatty liver, retatrutide lowered the amount of fat in the liver by around 81% to 82% at the higher doses over about six months (24 weeks). To put real numbers on it, the studied doses cut liver fat by about 81% at the 8 mg dose and about 82% at the 12 mg dose. That means most of the excess fat in the liver was gone. And it was not a rare result: roughly 79% of people on the 8 mg dose and about 86% on the 12 mg dose ended up with a normal level of liver fat — under 5% — by the end.
That is a big result, and the three-signal design may be part of why. One of the signals retatrutide copies — glucagon — nudges the liver to burn off its own stored fat. So the drug seems to work on the liver fairly directly, not just as a side effect of losing weight overall.
Still, the same caution applies. This was early research in a limited group of people. It tells us the drug can move liver fat in the right direction. It does not yet prove what that means for long-term liver health, and it is not a reason to seek out an unapproved drug on your own.
What about blood pressure, cholesterol, and blood sugar?
Beyond weight and liver fat, the early studies also tracked a handful of general health markers — the kind of numbers a doctor checks at a regular visit. Broadly, these tended to move in a healthy direction.
Researchers reported improvements in blood pressure (the force of blood pushing against your artery walls), in cholesterol and other blood fats, and in blood sugar (the amount of sugar in your blood, which matters a lot for diabetes). In plain terms, the parts of a routine checkup that you want to see improve generally did.
It is worth being honest about how to read this. These were described in general terms as part of the bigger studies, not as the single main question each study was built to answer. So the right takeaway is gentle: alongside the weight and liver results, the broader health picture in these early studies pointed the same encouraging way. That is a reason for scientists to keep studying it — not a guarantee for any individual.
What did the diabetes studies add?
Most of the headline numbers above come from studies in people with obesity. But retatrutide was also tested in a separate early study of adults living with type 2 diabetes — a condition where blood sugar runs too high. That study asked a slightly different question: not just weight, but how well the drug controlled blood sugar.
The main blood-sugar measure doctors use is called HbA1c (often shortened to A1c). Think of it as a roughly three-month average of your blood sugar. In that diabetes study, people on the highest weekly dose saw their HbA1c fall by about 2 percentage points over 24 weeks — a large move for that kind of marker. Their weight dropped too, by around 17% at the highest dose.
A couple of honest notes. This was again an early-stage (phase 2) study, so the same "the big numbers often shrink later" caution applies. And the weight figure here — about 17% — is lower than the roughly 24% seen in the obesity study, which is a normal reminder that results differ between different groups of people. Even so, the diabetes findings pointed the same encouraging direction: better blood sugar alongside meaningful weight loss. As with everything on this page, that is trial data about an experimental drug, not a promise or a recommendation.
The big caveat: investigational, not proven or approved
Here is the part that matters most, so it gets its own section. Everything above describes what early studies observed. None of it makes retatrutide a proven, approved, or available medicine. It is still investigational, which is just the formal word for "still being tested."
The next stage of testing is now underway. A large phase 3 program — the big, final round of studies, called TRIUMPH — is running across several trials with more than 5,800 people in total. Those studies are looking at different groups, including people with obesity, people who also have obstructive sleep apnea (a serious sleep-and-breathing condition), people with obesity and heart disease, and people with obesity and knee arthritis. The fact that these studies are still ongoing is exactly why retatrutide is not approved. The verdict is not in yet.
And remember the pattern from earlier: the eye-catching numbers from small early studies often come down somewhat in these larger, longer ones. That is normal and expected. It does not mean the drug failed — it means we are still learning the real, everyday-sized answer.
So please read this whole page as a science update, not a recommendation. Because retatrutide is only available inside clinical trials, joining one of those studies is the only lawful way to receive it right now. Whether any weight medicine is right for a person — approved or experimental — is a decision for a licensed clinician who knows that person's full history. Nothing here is medical advice, and nothing here is a nudge to use it.
Tracking a metabolic protocol on PeptidePanel
PeptidePanel does not sell, supply, prescribe, or recommend any drug, and nothing here is medical advice. We are simply a tracking tool. If a clinician has someone on a protocol in this family of medicines — whether that is an approved drug today or an experimental one inside a trial — there is a lot to keep straight.
That is where careful tracking earns its keep: logging each dose, watching weight and waist measurements trend over weeks, and keeping an eye on the lab numbers a clinician follows, like liver enzymes, blood sugar, and cholesterol. PeptidePanel is the neutral notebook for exactly that. It records the plan a clinician set, charts the results against normal ranges, and surfaces the trends worth discussing at the next appointment. It does not replace that appointment — it makes it more useful.